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Cell Biology/Signaling
Matrix Metalloproteinase-10 Is Upregulated by Thrombin in
Endothelial Cells and Increased in Patients With Enhanced
Thrombin Generation
Josune Orbe, Jose´ A. Rodríguez, Olivier Calvayrac, Ricardo Rodríguez-Calvo, Cristina Rodríguez,
Carmen Roncal, Sara Martínez de Lizarrondo, Jaione Barrenetxe, Juan C. Reverter,
Jose´ Martínez-Gonza´lez, Jose´ A. Pa´ramo
Objective—Thrombin is a multifunctional serine protease that promotes vascular proinflammatory responses whose effect
on endothelial MMP-10 expression has not previously been evaluated.
Methods and Results—Thrombin induced endothelial MMP-10 mRNA and protein levels, through a protease-activated
receptor-1 (PAR-1)–dependent mechanism, in a dose- and time-dependent manner. This effect was mimicked by a
PAR-1 agonist peptide (TRAP-1) and antagonized by an anti–PAR-1 blocking antibody. MMP-10 induction was
dependent on extracellular regulated kinase1/2 (ERK1/2) and c-jun N-terminal kinase (JNK) pathways. By serial
deletion analysis, site-directed mutagenesis and electrophoretic mobility shift assay an AP-1 site in the proximal region
of MMP-10 promoter was found to be critical for thrombin-induced MMP-10 transcriptional activity. Thrombin and
TRAP-1 upregulated MMP-10 in murine endothelial cells in culture and in vivo in mouse aorta. This effect of thrombin
was not observed in PAR-1–deficient mice. Interestingly, circulating MMP-10 levels (P0.01) were augmented in
patients with endothelial activation associated with high (disseminated intravascular coagulation) and moderate
(previous acute myocardial infarction) systemic thrombin generation.
Conclusion—Thrombin induces MMP-10 through a PAR-1–dependent mechanism mediated by ERK1/2, JNK, and AP-1
activation. Endothelial MMP-10 upregulation could be regarded as a new proinflammatory effect of thrombin whose
pathological consequences in thrombin-related disorders and plaque stability deserve further investigation. (Arterioscler
Thromb Vasc Biol. 2009;29:2109-2116.)
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There is growing evidence for an intimate link betweeninflammatory and coagulation pathways in vascular dis-
ease. Inflammation appears to shift the hemostatic mecha-
nisms in favor of thrombosis, and conversely, coagulation
pathways influence inflammatory response.1–3 Thrombin par-
ticipates in this interplay and, besides its well established role
in thrombosis and hemostasis, activates protease-activated
receptors (PARs) and elicits multiple effects in a variety of
cell types.1 PARs have been implicated in the control of
vascular tone, vascular permeability, and secretory activity
of endothelial cells.4–6 In addition, the activation of PARs
induces the production of proinflammatory cytokines, up-
regulates cell adhesion molecules, and promotes leukocyte
rolling in different models.7–9 PAR-1 seems to be the major
mediator of thrombin signaling in vascular endothelial cells
(ECs) in mice and humans, and most of the actions of
thrombin on ECs have been reproduced using the PAR-1
agonist peptides.10
Thrombin exerts powerful proinflammatory effects on
vascular cells and upregulates some matrix degrading metal-
loproteinases (MMPs).11–13 MMPs are zinc-dependent endo-
peptidases capable of degrading extracellular matrix (ECM)
proteins, but also process a number of bioactive molecules.
They are known to be involved in the cleavage of cell surface
receptors, the release of apoptotic ligands (such as the FAS
ligand), and chemokine in/activation. MMPs are also thought
to play a major role on cell proliferation, migration, differ-
entiation, angiogenesis, apoptosis, and host defense.14,15
MMPs also participate in the maintenance of vascular pa-
tency after a thrombotic event, which requires fibrin removal
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by a cooperative proteolytic processing involving plasmin
and MMPs.16
Recently, we demonstrated that MMP-10 is associated with
inflammation and subclinical atherosclerosis and is present in
atherosclerotic lesions at rupture-prone sites.17,18 MMP-10
(stromelysin-2) is a protease that processes various compo-
nents of basement membrane matrix such as collagen type IV,
laminin, and proteoglycans and activates other MMPs
(MMP-1, -8, and -13) capable of degrading interstitial com-
ponents of ECM.19,20 However, little is known on its patho-
physiological role in thrombotic disorders. In this study we
investigated whether human thrombin is able to induce
MMP-10 in ECs and in pathological conditions characterized
by increased thrombin generation. Our results provide novel
insights into the molecular mechanisms underlying vascular
effects of thrombin and highlight the potential relevance of
MMP-10 in processes associated to local and systemic
thrombin generation.
Methods
Detailed explanation of the different experimental procedures is
provided as supplementary material (available online at
http://atvb.ahajournals.org).
Cell Cultures
Human umbilical vein endothelial cells (HUVECs), human aortic
endothelial cells (HAECs), bovine aortic endothelial cells (BAECs),
and mouse lung endothelial cells (MLECs) were arrested overnight
and stimulated with human thrombin. When needed cells were
pretreated for 30 minutes with different inhibitors of signaling
pathways.
Real-Time PCR
RNA from cells was extracted and reverse-transcribed. Real-time
PCR was performed using TaqMan gene expression assays-on-
demand (Applied Biosystems).
MMP-10 Protein Secretion
MMP-10 levels were assayed in conditioned medium by ELISA
(R&D Systems). Cell culture and serum samples were diluted 1:5
and 1:2 respectively. The assay recognizes the zymogens and active
forms.
Western Blot Analysis
Protein extracts from HUVECs stimulated with thrombin in the
presence or in the absence of hirudin and ATAP2 were analyzed by
Western blot. Antibodies against ERK1/2 and JNK-1 (either phos-
phorylated forms of total protein) were used.
MMP-10 Promoter Constructs and Transient
Transfection Assays
A 2.0-kb fragment of the human MMP-10 promoter was generated
by PCR and cloned into pGL-3 vector (Promega). A series of
promoter deletions were generated, and the putative AP-1 site
present in MMP-10 promoter was mutated using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene). HUVECs or BAECs
were transfected with the luciferase reporter plasmids and stimulated
with thrombin in the presence or absence of inhibitors. Luciferase
activity was measured in cell lysates using the Luciferase assay kit
(Promega) and a luminometer (Orion I, Berthold Detection Systems).
Results were normalized by -galactosidase activity using the
Enzyme Assay System (Promega).
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assays (EMSAs) were carried out
using nuclear extracts from HUVECs stimulated with thrombin in
the presence or in the absence of different pathway inhibitors.
Doubled stranded probes containing the putative AP-1 element
present in MMP-10 were labeled with [-32P]-ATP and T4 polynu-
cleotide kinase and protein-DNA complexes were resolved by
electrophoresis.
Induction of MMP-10 by Thrombin in Mouse
Aorta: In Vivo Assay
Thrombin (0.1 to 10 U) or TRAP-1 (6 mg/kg) were infused intravenously
to wild-type mice (C57Bl/6). PAR-1-deficient (PAR-1/) mice, kindly
provided by Dr R. Chambers (University College, London, UK),21
were also treated with thrombin or saline. MMP-10 in aorta was
assessed by real-time PCR and immunohistochemistry. The research
was performed in accordance with the European Community guide-
lines for ethical animal care and use of laboratory animals (Directive
86/609) and was approved by the University of Navarra Animal
Research Review Committee.
Circulating MMP-10 Levels in Patients
MMP-10 was measured by ELISA (R&D Systems) in serum from 60
patients with previous acute myocardial infarction (previous AMI)
and 12 patients with sepsis-induced disseminated intravascular
coagulation (DIC). Another 2 groups of healthy subjects were
included, matched for age and sex. Informed consent was obtained
from all subjects according to the Declaration of Helsinki.
Statistical Analysis
Continuous variables were expressed as meanSD (unless otherwise
stated). Differences between groups were assessed by using appro-
priate statistical tests (SPSS version 11.0). Statistical significance
was established as P0.05.
Results
Thrombin Induces MMP-10 mRNA Levels in
Human Endothelial Cells
Thrombin increased MMP-10 mRNA levels in HUVECs in a
time- and dose-dependent manner (Figure 1A). The effect
was statistically significant at 2 hours (P0.01) reaching a
maximum at 6 hours (P0.01) compared to control, and was
prevented by hirudin (a specific thrombin inhibitor). In
contrast, no significant changes in TIMP-1 expression could
be observed (data not shown). Thrombin also increased
MMP-10 protein levels, an effect that was significant
(P0.01) 12 hours after stimulation (Figure 1B). Similarly,
thrombin induced both MMP-10 mRNA and protein levels in
adult HAECs, an effect that was prevented by hirudin (Figure
1C). In these cells, 0.1 U/mL thrombin promoted a 5-fold
increase in MMP-10 mRNA at 12 hours and a 3-fold increase
in MMP-10 protein. Actinomycin D blocked thrombin-
induced MMP-10 upregulation, and no changes in MMP-10
mRNA half-life were observed (data not shown).
PAR-1 Mediates the Upregulation of MMP-10
by Thrombin
PAR-1 blocking antibody ATAP2 completely neutralized
thrombin-induced MMP-10 mRNA and protein (Figure 2A),
whereas a control antibody (N-19) did not produce any effect.
Moreover, a short peptide agonist for human PAR-1
(TRAP-1) mimicked the effect of thrombin on endothelial
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MMP-10 expression, whereas a peptide agonist for human
PAR-2 (PAR2-AP) had no effect (Figure 2A). Taken to-
gether, these results indicate that thrombin upregulates endo-
thelial MMP-10 via PAR-1.
MAPK Pathways Are Involved in
Thrombin-Induced MMP-10 Gene Expression
Because thrombin activates different signaling pathways in
ECs, specific inhibitors were used to address which of these
pathways are involved in MMP-10 induction. Results shown
in Figure 2B indicate that MMP-10 induction by thrombin
was dependent on ERK1/2 (inhibited by PD98059) and JNK
(inhibited by SP600125). By contrast, SB203580 (inhibitor of
p38 MAPK) and wortmannin (inhibitor of PI3K) did not
significantly affect MMP-10 response to thrombin. In the
absence of thrombin, inhibitors did not produce any effect on
MMP-10 levels (data not shown). Thrombin and TRAP-1
activated ERK1/2 and JNK-1 phosphorylation in a time-
dependent manner, whereas hirudin and ATAP2 completely
prevented thrombin-induced activation of these signaling
kinases (Figure 2C). Therefore, these results indicate that
thrombin upregulates MMP-10 through a PAR-1–dependent
mechanism mediated by ERK1/2 and JNK.
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Figure 1. Thrombin induces MMP-10 mRNA and protein levels
in vascular endothelial cells. A, Time-course and dose-response
showing the increase of MMP-10 mRNA levels after incubation
of HUVECs with thrombin (Thr, 0.1 to 5 U/mL) for 1 to 12 hours
in the presence or absence of hirudin (Hir): circles (Thr 0.1
U/mL); squares (Thr 2.5 U/mL); diamonds (Thr 5 U/mL); triangles
(Thr 0.1 U/mL  Hir). B, MMP-10 protein in the conditioned
medium from cells treated as indicated in A. C, Thrombin (0.1
U/mL, 12 hours) increased MMP-10 mRNA (left) and protein
(right) by human aortic endothelial cells (HAECs), effects that
were prevented by hirudin. Data (meanSEM, n4) are present-
ed as percentage from controls. P0.01: * vs control; † vs
thrombin alone.
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Figure 2. Thrombin upregulates MMP-10 through a PAR-1–de-
pendent mechanism. A, PAR-1 mediates thrombin-induced
MMP-10 expression in endothelial cells. The effect of thrombin
(0.1 U/mL,12 hour) on MMP-10 mRNA (white bars) and protein
(black bars) was mimicked by a PAR-1 agonist peptide (TRAP-1)
and inhibited by a PAR-1 blocking antibody (ATAP2). The
absence of effect of a control antibody against PAR-1 (N-19) or
a PAR-2 agonist (PAR2-AP) is also shown. P0.01: * vs control;
† vs thrombin alone. B, ERK1/2 and JNK signaling pathways are
involved in thrombin-induced MMP-10 expression. Real-time
PCR showing MMP-10 mRNA levels in HUVECs induced with
thrombin in the presence of different inhibitors: PD98059 (PD),
SP600125 (SP), SB203580 (SB), and wortmannin (Wor). Data are
meanSD (n5). P0.05: * vs controls; † vs thrombin alone. C,
Thrombin activates ERK1/2 and JNK signaling pathways. West-
ern blot analysis showing the time-dependent activation of
ERK1/2 and JNK-1 in HUVECs stimulated with thrombin or
TRAP-1. Activation of ERK1/2 and JNK-1 by thrombin (5 min-
utes) is prevented by incubation with either hirudin or ATAP2.
Unchanged levels of total ERK1/2 (t-ERK1/2) and total JNK-1
(t-JNK-1) are shown.
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Involvement of AP-1 in the Induction of MMP-10
by Thrombin
To further characterize the mechanisms underlying MMP-10
upregulation by thrombin we performed transient transfection
assays using a luciferase reporter plasmid containing
MMP-10 promoter (pMMP10/-1934). In these experiments
thrombin (5 U/mL) increased MMP-10 promoter activity
more than 2-fold over controls in both HUVECs and BAECs,
an effect that was mimicked by TRAP-1 (Figure 3A). In
addition, ATAP2 but not N19 abrogated the upregulation of
MMP-10 promotor activity induced by thrombin in HUVECs.
The effect of thrombin was dose- and time-dependent, reach-
ing a maximum 10 hours after thrombin stimulus (Figure 3B).
Thrombin-induced activity of MMP-10 promoter was pre-
vented by PD98059 and SP600125, but not by SB203580 or
wortmannin (Figure 3C). To determine the element respon-
sive to thrombin in the MMP-10 promoter, we constructed a
series of promoter deletions and examined their activity in
transient transfection experiments (Figure 4A). The con-
structs pMMP-10/-1934, -456, -350, and -251 exhibited
similar basal promoter activity that was increased by 2-fold
after thrombin induction. However, the construct pMMP-
10/-47 showed a markedly reduced basal activity with no
significant changes after thrombin treatment. We identified
several potential transcription factor binding sites within the
proximal promoter region of MMP-10, spanning nucleotides
-251 to -47 including a cAMP response element (CRE) and a
response element for AP-1 (Jun/Fos heterodimer). Mutation
of the CRE site did not affect thrombin-induced MMP-10
transcriptional activity (data not shown). By contrast, muta-
tion of the AP-1 site ([-67]TGAATCA[-61]) by site-directed
mutagenesis significantly reduced both basal and thrombin-
induced MMP-10 promoter activities (Figure 4A). Consistent
with this, NDGA (AP-1 inhibitor) significantly reduced both
thrombin-induced mRNA and the transcriptional activity of
MMP-10 promoter in transient transfection assays (Figure 4B
and 4C). By EMSA we show that thrombin increases the
binding to this AP-1 response element in a time-dependent
manner. AP-1 binding was verified by antibody supershift
assays and was abrogated by site-directed mutagenesis (Fig-
ure 4D). Finally, AP-1 binding to this response element was
reduced by PD98059, SP600125, and NDGA, compounds
that inhibit ERK1/2, JNK-1, and AP-1, respectively, and
reduce thrombin-induced MMP-10 mRNA levels.
Thrombin Induces Vascular MMP-10 Expression
In Vivo
Thrombin increased MMP-10 mRNA levels in mouse endo-
thelial cells in a dose-dependent manner (Figure 5A). This
effect was mimicked by TRAP-1 and was completely pre-
vented by hirudin. MMP-10 mRNA upregulation by thrombin
and TRAP-1 was also reduced by PD98059 and SP600125.
To determine whether thrombin is able to induce MMP-10 in
vivo, we analyzed the expression of MMP-10 in the aorta of
mice 6 hours after i.v. administration of thrombin (0.1 to 10
U) or TRAP-1 (6 mg/kg). The expression of MMP-10 in the
aorta of saline-treated control mice was undetectable by
real-time PCR, but thrombin strongly induced MMP-10
mRNA in a dose-dependent manner (Figure 5B). The effect,
mimicked by TRAP-1, was observed even at the lowest dose
of thrombin administered (0.1 U) and was maximum at the
higher dose used (10 U), although the later was associated
with a high mortality rate (2 of 4 mice) likely as a result of
DIC, as assessed by the presence of diffuse petechial intra-
abdominal hemorrhage. By contrast, high doses of thrombin
were unable to induce MMP-10 mRNA in PAR-1/ mice.
MMP-10 mRNA induction by thrombin was followed by an
increase in MMP-10 protein levels. Indeed, immunohisto-
chemical analysis clearly showed the increase of MMP-10 in
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Figure 3. Thrombin induces MMP-10 promoter activity in endo-
thelial cells. The effect of thrombin (5 U/mL) on the activity of
MMP-10 promoter (construct pMMP10/-1934) was assayed in
transient transfection experiments. A, Thrombin and TRAP-1
increase MMP-10 promoter activity in both HUVECs and
BAECs. This effect was completely prevented by a PAR-1
blocking antibody (ATAP2). The absence of effect of a control
antibody against PAR-1 (N-19) is also shown. B, Time- and
dose-dependent effect of thrombin on MMP-10 promoter activ-
ity in HUVECs. C, Effect of inhibitors of different signaling path-
ways on MMP-10 promoter activity in HUVECs transfected with
pMMP10/-1934 and treated with thrombin for 10 hours.
PD98059 (PD), SB203580 (SB), SP600125 (SP), and wortmannin
(Wor) were used as described in Figure 2 legend. Data are
meanSD (n5). P0.05: * vs controls; † vs thrombin alone.
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the intima (endothelial cells and subendothelium) of aortic
sections from thrombin-treated animals (Figure 5C), indicat-
ing that thrombin is able to induce vascular MMP-10 expres-
sion in vivo.
Circulating Levels of MMP-10 in
Thrombin-Related Clinical Disorders
To further demonstrate whether increased thrombin genera-
tion is associated with elevated MMP-10 levels in patholog-
Figure 4. AP-1 is involved in thrombin-induced MMP-10 upregulation. HUVECs were transiently transfected with MMP-10 constructs
and stimulated with thrombin (5 U/mL, 10 hours). A, MMP-10 promoter activity of various deletion mutants in the presence (black bars)
or in the absence (white bars, controls) of thrombin. Constructs are numbered and named according to their length upstream of the
transcription-initiation site. The activity of pMMP10/-1934 and pMMP10/-350 constructs and the same constructs mutated in the AP-1
site (-67/-61) is shown. P0.05: * vs control cells transfected with the same construct; † vs cells transfected with the corresponding
wild-type construct (nonmutated) and induced with thrombin. Data are meanSD (n5). The location of the putative response elements
is indicated: serum response element (SRE), cAMP response element binding protein (CREB), and activator protein-1 (AP-1) site. Lucif-
erase activity is expressed as fold-change using pMMP10/-350 (mutated in AP-1 in the absence of stimulus) as a reference value.
B and C, Effect of NDGA on MMP-10 mRNA levels (B) and MMP-10 promoter activity (C) induced by thrombin (5 U mL for 10 hours).
P0.05: * vs controls; † vs thrombin. Data are meanSD (n5). D, Thrombin induces the binding activity to a putative AP-1 site (-67/-
61) present in MMP-10 promoter. The binding to this site was evaluated by EMSA using nuclear extracts from HUVECs stimulated with
thrombin (5 U/mL) for increasing times (upper left panel). The binding observed using the wild-type sequence of MMP-10 promoter (WT
probe) was abolished when the AP-1 site was mutated (Mut probe; lower left panel). The effect of PD98059, NDGA, and SP600125 on
AP-1 binding was also analyzed. A supershifted band was observed on addition of a specific antibody against Jun (AB). Competition
using a 100-fold (100) excess of unlabeled probe is also shown. Arrowheads indicate the position of the specific shifted band (s), the
supershifted band (ss), and the free probe (fp).
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ical situations, a small series of patients with well character-
ized DIC-related sepsis as well as patients with previous AMI
were analyzed and compared with age- and sex-matched
healthy subjects. Patients with DIC (n12) showed reduced
platelet count (139.792.6 109/L), decreased prothrombin
(57.819.7%) and antithrombin activities (35.78.3%), and
elevated levels of C-reactive protein (hsCRP) (16.613.0
mg/L) and plasma D-dimer (2044.3647.8 ng/mL), indicat-
ing an acute inflammatory status associated with systemic
thrombin generation and fibrin degradation, typical of overt
DIC. MMP-10 levels were significantly higher than in controls
(n50) when crude analysis was performed (1682.61713.5
[median1412.2, IQR1574.3] versus 573.1170.0 pg/mL
[median557.9, IQR237.7], P0.05). Further ANCOVA
analysis, controlling for age and sex, revealed highly statistically
significant differences in MMP-10 levels (1799.1237.4 versus
542.7116.0 pg/mL, P0.001) between groups (Figure 6A).
To assess indirectly whether plasmin, which is increased in
DIC, could affect MMP-10 activity, in vitro experiments
were carried out coincubating rMMP-10 and plasmin. West-
ern blot analysis showed a single band of 45 kDa correspond-
ing to fully activated MMP-10 after plasmin addition, which
was corroborated in an MMP-10 activity assay (supplemental
Figure I).
We also measured MMP-10 levels in a group of patients
with previous AMI (n60) and enhanced thrombin genera-
tion (thrombin peak, 615.526.1 nmol/L versus 497.437.2
nmol/L, P0.01)22 (Figure 6B). MMP-10 levels were in-
creased in these patients as compared to controls (765.3
386.7 pg/mL versus 546.12119.0 pg/mL, P0.01), which
remained statistically significant after adjustment for age and
sex (P0.01, Figure 6C). In patients with previous AMI,
MMP-10 positively correlated with inflammatory marker
hsCRP (r0.30, P0.05) as well as with the thrombin
generation index (r0.31, P0.05). Finally, as a control of
Figure 5. Thrombin induces MMP-10 mRNA levels in both
mouse lung endothelial cells (MLECs) and mouse aorta. A,
Thrombin increases MMP-10 mRNA levels in MLECs in a
concentration-dependent manner. This effect was prevented by
either hirudin, PD98059 (PD), and SP600125 (SP). The induction
of MMP-10 expression by the PAR-1 agonist peptide (TRAP-1)
and its prevention by PD and SP is also shown. Data are
meanSD (n5). B, i.v. thrombin injection induces MMP-10
mRNA levels in the aorta of wild-type mice 6 hours after admin-
istration (shaded bars) but had no effect in PAR-1/ mice
(black bars). TRAP-1 (6 mg/kg) elicits a similar response to
thrombin. Because after 40 cycles of amplification no expres-
sion was detected in vessels from control animals (Control), a
reference value of 1 was assigned to these samples. P0.05: *
vs controls; † vs 0.1 and 1 U/mL thrombin. C, Immunohisto-
chemistry for MMP-10 in murine aortic sections. MMP-10 immu-
noreactivity was clearly detected in endothelial cells and suben-
dothelium (arrows) of aortic sections from mice receiving an i.v.
injection of 5 U thrombin (right) but not in the arterial wall of
control animals (left). L indicates vessel lumen.
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Figure 6. Circulating levels of MMP-10 are increased in patients
with high systemic thrombin generation. A, Circulating MMP-10
levels (pg/mL, meanSEM) in patients with disseminated intra-
vascular coagulation (DIC) and controls after adjusting for age
and sex. B, Representative thrombogram profiles as assessed
by the thrombin generation test in control subjects and patients
with previous acute myocardial infarction (AMI). C, Circulating
MMP-10 levels (pg/mL, meanSEM) in AMI patients and
controls.
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endothelial activation we show that circulating levels of von
Willebrand factor (vWF), a marker of endothelial activation/
injury that has been shown to be induced by thrombin, were
increased in patients with either DIC or previous AMI
(supplemental Table I).
Discussion
MMP-10 (stromelysin-2) degrades a broad range of ECM
proteins and plays an important role in cancer progression,
invasion, and metastasis, liver fibrogenesis, capillary tube
regression, wound repair, and maintenance of vascular integ-
rity.23–26 Recently, our group reported that CRP induces
MMP-10 in human ECs, linking inflammation and proteoly-
sis at cellular level.17 We also found that circulating MMP-10
levels correlate with systemic inflammatory markers and
carotid intima-media thickness (IMT) in apparently healthy
subjects.17,18 Here we report that thrombin, via PAR-1,
markedly enhances expression and secretion of MMP-10 in
ECs, both in vitro and in vivo, and that circulating MMP-10
levels are increased in patients with high (DIC) and moderate
(previous AMI) systemic thrombin generation.
Thrombin is a multifunctional serine protease involved not
only in the cleavage of fibrinogen to fibrin and clot formation
but also in activating a variety of cell types, including ECs.27
Thrombin signaling in the endothelium results in a variety of
phenotypic changes, including alterations in cell shape, per-
meability, migration, angiogenesis, and hemostasis.28 Throm-
bin selectively enhanced MMP-10 mRNA and protein levels
in human ECs, with no changes in TIMP-1 expression. The
specificity of the thrombin effect was assessed in vitro by the
following experiments: (1) addition of direct thrombin inhib-
itor hirudin completely blocked the increase of MMP-10
induced by thrombin, (2) the effect was mimicked by a
synthetic PAR-1 agonist, and (3) MMP-10 induction was
inhibited by a PAR-1 blocking antibody (ATAP2). Therefore,
our results show that MMP-10 induction by thrombin re-
quires PAR-1. Because activation of PAR-1 promotes proin-
flammatory, proangiogenic, and transforming pathways,29,30
it might be suggested that MMP-10 could be a mediator of
thrombin-induced proinflammatory responses. Finally, under
our experimental conditions thrombin was also able to induce
MMP-9 mRNA and protein levels (supplemental Figure II),
in agreement with previous data reported in other cell types,31
emphasizing the potential role of thrombin in vascular remod-
eling by modulating MMP expression.
Regarding the molecular mechanisms by which thrombin,
via PAR-1, leads to endothelial MMP-10 upregulation, our
results involve JNK and ERK1/2. The inhibition of thrombin-
induced MMP-10 mRNA upregulation by actinomycin D
indicates that thrombin increases MMP-10 transcription rate.
Indeed, in transient transfection experiments thrombin in-
duced the transcriptional activity of a MMP-10 promoter
construct, an effect that was prevented by inhibitors of
ERK1/2 pathway and JNK. It has been shown that thrombin
is able to modulate gene expression in vascular cells by
activating a number of transcription factors including AP-1
and CRE binding protein (CREB).6 In silico analysis of the
proximal region of the MMP-10 promoter reveals the pres-
ence of putative response elements for several transcription
factors, including CREB and AP-1.15 By mutation deletion
analysis and site-directed mutagenesis we identified an AP-1
site that is critical in thrombin-induced MMP-10 expression.
Furthermore, EMSA studies demonstrate that thrombin in-
creases the binding of AP-1 to this site through the activation
of ERK1/2 and JNK pathways. Therefore, our results agree
with those demonstrating that PAR-1 stimulates ERK1/2 and
JNK pathways and activates AP-1, a transcription factor
involved in thrombin-induced gene expression associated to
different cellular effects triggered by this serine protease,
including proinflammatory, proangiogenic, and transforming
pathways.29,30
We then used a mouse model to study MMP-10 expression
in the vascular wall and find out whether thrombin was able
to induce MMP-10 after intravenous injection. Thrombin
upregulated MMP-10 mRNA levels in the aorta of wild-type
mice and increased MMP-10 protein in the subendothelium.
In vivo MMP-10 induction was reproduced by TRAP-1
administration but was not observed in PAR-1/ mice
treated with thrombin, further supporting the involvement of
PAR-1 and suggesting that MMP-10 could be implicated in
processes associated with thrombin generation and ECM
degradation in vivo.3 In this regard, to assess MMP-10 in a
clinical setting, circulating MMP-10 levels were measured in
patients with thrombin-related disorders, namely sepsis-
related DIC and AMI, both characterized by increased throm-
bin generation and endothelial activation.22 Interestingly, we
found a 3-fold increase in MMP-10 levels in DIC patients, as
compared to age- and sex-matched control subjects. The
ability of MMPs to destroy isolated clotting factors and
inhibitors suggests that in certain types of DIC direct prote-
olysis rather than consumption of clotting factors may be
operational.32,33 Other MMPs, such as MMP-3, the highest
one homologous with MMP-10, have been shown to play a
role in the regulation of cellular fibrinolysis.34 In addition,
MMP-10 was enhanced in patients with previous AMI and
correlated with hsCRP as well as with the thrombin genera-
tion index, suggesting that MMP-10 may be a link between
systemic inflammation and thrombin generation in athero-
thrombotic syndromes.35
In summary, the present findings confirm and extend our
previous observations pointing out MMP-10 as a novel
biomarker for cardiovascular disorders and show for the first
time the molecular mechanisms that connect thrombin with
MMP-10, which has recently emerged as a new player in
inflammation and vascular integrity.25,26,36 Further studies are
needed to establish whether MMP-10 is critical for mediating
the effects of thrombin on vascular remodeling, inflamma-
tion, or angiogenesis and to define the role of this MMP in the
pathophysiology of thrombin-related disorders and plaque
stability.
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SUPPLEMENT MATERIAL. METHODS 
Cell cultures  
Human umbilical vein endothelial cells (HUVEC) were isolated from human umbilical 
cords by digestion with collagenase A (Invitrogen), cultured as described and used 
between passages 3 and 51. Human artery endothelial cells (HAEC, Cambrex 
BioScience) and bovine aortic endothelial cells (BAEC, Cambrex BioScience) were 
grown in endothelial growth medium (EGM-2, Cambrex) according to the 
manufacturer’s instructions. Mouse lung endothelial cells (MLEC) were isolated from 
the lungs of C57BL/6 mice by collagenase digestion followed by selection with ICAM-
2-coated magnetic beads. Briefly, lungs were excised and finely minced prior to 
collagenase A (0.1%) digestion at 37ºC for 1 hour under shaking. Digested tissue was 
homogeneized by a 14G syringe and homogenates were centrifuged at 200 ×g for 5 min. 
Then, the cell pellet was extensively washed and seeded in a gelatin-coated flask. After 
6 days in culture, endothelial cells were recovered and selected using DynabeadsTM M-
450 (Dynal Biotech) coupled to anti-ICAM-2 (Pharmingen). MLEC were cultured in 
DMEM:F12 supplemented with 20% FCS, 30 µg/mL endothelial cell growth 
supplement (ECGS, Sigma), 100 µg/mL heparin (Sigma) and antibiotics. Cell purity 
was assessed by FACS analysis using antibodies against ICAM-2 (Dako) and CD31 
(Dako).  
Cells were seeded in multi-well plates and at confluency were arrested 
overnight, afterwards were stimulated with human recombinant thrombin (0.1-10 U/ml; 
Enzyme Research Laboratory) or agonists in the presence or absence of inhibitors. 
Thrombin effects were inhibited using recombinant hirudin (2 µM, Refludan, Schering 
AG) or antibodies against PAR-1 (2.5 µg/mL, ATAP2, Santa Cruz)2. Control antibody 
(2.5 µg/mL, N-19, Santa Cruz) against an N-terminal epitope of PAR-1 was used.  
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PAR-1 and PAR-2 agonist peptides, TRAP-1 (TFLLRNPNDK; 50 µM) and PAR2-AP 
(SLIGRL; 100 µM) respectively, generated as described3, were also used. When 
needed, cells were pre-treated with inhibitors of signaling pathways for 30 minutes 
(unless otherwise stated). The inhibitors used were: 10 µM PD98059 (a mitogen-
extracellular kinase-1/2 [MEK1/2] inhibitor, Calbiochem); 10 µM SB203580 (a p38 
mitogen-activated protein kinase [MAPK] inhibitor, Calbiochem), 10 µM SP600125 (a 
c-Jun N-terminal kinase [JNK] inhibitor, BioSource), 1 µM wortmannin (a 
phosphatidylinositol-3 kinase [PIK3] inhibitor, Sigma), and 0.5 µg/mL 
nordihydroguaiaretic acid (NDGA, an inhibitor of activator protein-1 [AP-1], Sigma). 
Finally, actinomycin D (4 µM, Sigma) was used to determine whether thrombin effects 
were due to changes in transcription rate. 
 
Real-Time PCR 
RNA from cells was extracted using a semi-automated system for the isolation and 
purification of nucleic acids (Abi Prism 6100, Applied Biosystems) and reverse 
transcription was performed with 1 µg of total RNA, random primers and Moloney 
Murine Leukemia Virus (MMLV) reverse transcriptase (Invitrogen). Real-time PCR 
was performed on an ABI PRISM 7900 sequence detector (Applied Biosystems) using 
TaqMan™ gene expression assays-on-demand (Applied Biosystems) for MMP-10 
(human: Hs00233987_m1; mouse: Mm00444630_m1), MMP-9 (Hs00957562_m1) and 
TIMP-1 (Hs00171558_m1). Human glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH, 4326317E) or murine β-actin (4352341E) were used to normalize results. 
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MMP-10 protein secretion 
MMP-10 levels were assayed in conditioned medium and serum by ELISA (Quantikine, 
R&D systems). Cell culture and serum samples were diluted 1:5 and 1:2 respectively, 
following the manufacturer’s instructions. MMP-9 levels were assayed in conditioned 
medium by ELISA (Quantikine, R&D systems). The assays recognize the zymogens 
and active forms. Inter and intra-assay coefficients of variation for the ELISA were 
<6%.  
 
Western blot analysis 
HUVEC were stimulated with thrombin or TRAP-1 in the presence or in the absence of 
hirudin and ATAP2 and protein extracts were analyzed by western blot as described4. 
Briefly, cell cultures were washed twice with wash buffer (50 mM Hepes pH 7.4, 150 
mM NaCl, 100 mM NaF, 10 mM NaPPi, 10 mM EDTA, 2 mM Na3VO4) and lysed with 
lysis buffer (wash buffer containing 1 mM PMSF, 5 µM leupeptin, 1% triton X-100). 
Protein concentration was measured by the bicinchoninic acid (BCA) protein assayTM 
(Pierce). Proteins were separated by SDS-PAGE (12.5% acrylamide:bisacrylamide 
37.5:1) and electrotransferred onto nitrocellulose membranes (Bio-Rad Laboratories). 
Blots were incubated with antibodies against human phosphorylated ERK1/2 (p-
ERK1/2; Cell Signaling Technology), total human ERK1/2 (t-ERK1/2; Cell Signaling 
Technology), human phosphorylated JNK-1 (p-JNK-1; Cell Signaling Technology) or 
total human JNK-1 (Santa Cruz Biotechnology, Inc). Bound antibody was detected 
using the appropriate horseradish peroxidase-conjugated antibody (Dako) and a 
chemiluminescent detection system (Supersignal West DuraTM, Pierce).  
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Construct of MMP-10 promoter 
A 2.0 kb fragment corresponding to nucleotides –1934 to +66 of the human MMP-10 
promoter was generated by PCR and cloned into pGL-3 vector (Promega). The primers 
used were: 5´-GGATCCGAATTCGAGCTCTCGTATGGCAGCACAGTAGG-3’ 
(forward) and 5’-GGATCCGAATTCCTCGAGACAGCACAAGGAATGCAAGA-3’  
(reverse) (SacI and XhoI restriction enzyme cloning sites are underlined). A series of 
promoter deletions were generated using the reverse primer indicated above and the 
following forward primers: p-456, 5’-CTCAAGAGCTCAAGAAGTGAAATATTTG-
3’ (SacI site is underlined); p-350, 5’-GCGTTGGTACCTGCTTATATTTAAGTTT-3’ 
(KpnI site is underlined); p-251, 5-
TGTCAGCTAGCTTTAAGTAAATACAGAGACGTGAA-3’ (NheI site is underlined); 
p-47, 5’-TTGGTGAGCTCAGCATTGTCTCTGTATA-3’ (SacI site is underlined).  
The putative AP-1 site present in MMP-10 promoter was mutated using the 
QuikChangeTM Site-Directed Mutagenesis Kit (Stratagene) and the following 
oligonucleotide: (-88)-
CAGACTTAAAAAACACATGCAgGAAcCATACTGTTGGTGATCTCAGC-(-42) 
(changes introduced are indicated in lower case letters). The new sequence was 
analyzed by different promoter analysis softwares to confirm that no new response 
elements were generated.  
 
Transient transfection and luciferase reporter assay 
HUVEC or BAEC were seeded on six-well plates (180,000 cells/well) and were 
transfected with the luciferase reporter plasmids as described5. Briefly, the transient 
transfection assays were performed with 1 µg/well of plasmid and 4 µL of 
LipofectamineTM Reagent (Invitrogen, CA, USA). The complexes DNA/liposome were 
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added to the cells for 4 h, which were washed and incubated with complete medium for 
8 h. Afterwards, cells were incubated overnight in 5% FCS medium and stimulated with 
thrombin in the presence or absence of inhibitors. Luciferase activity was measured in 
cell lysates using the Luciferase assay kit (Promega) and a luminometer (Orion I, 
Berthold detection systems) according to the manufacturer. Results were normalized by 
β-galactosidase activity using the Enzyme Assay SystemTM (Promega). 
 
Electrophoretic mobility shift assay (EMSA) 
Nuclear extracts from HUVEC stimulated with thrombin in the presence or in the 
absence of different pathway inhibitors were obtained using the NucBuster Protein 
Extraction Kit (Novagen) according to the manufacturer’s recommendations. Proteins 
were quantified by the BCA protein assayTM (Pierce) and nuclear extracts were 
aliquoted and stored at -80ºC until used. The double-stranded DNA probe 
corresponding to the putative AP-1 binding site in MMP-10 promoter (in bold) and a 
mutated AP-1 probe (underlined bases) were generated from the annealing of the 
following single-stranded complementary oligonucleotides:  AP-1-wild-type (WT) 
upper strand: 5’-CACATGCATGAATCATACTGTTG-3’ and AP-1-WT lower strand: 
5’-CAACAGTATGATTCATGCATGTG-3’; AP-1-mutated (mut) upper strand: 5’-
CACATGCAGGAACCATACTGTTG-3’ and AP-1-mut lower strand: 5’-
CAACAGTATGGTTCCTGCATGTG-3’. Probes were end-labeled with [γ-32P]-ATP 
and T4 polynucleotide kinase as described 6.  EMSA assays were performed using the 
Novagen’s EMSA Accessory kit. Briefly, nuclear proteins (5 g) were incubated for 15 
min on ice with 0.01 U poly-d [I-C] and 1 µl sonicated Salmon Sperm DNA in 20 mM 
HEPES (pH 8), 0.2 mM EDTA, 100 mM KCl, 20% glycerol, and 0,5 mM DTT. 
Approximately 50000 cpm of the appropriate 32P end-labeled probe was then added to 
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the reaction mixture and incubated for 30 min on ice in a final volume of 20 l. For 
supershift assays, an anti-c-jun antibody (4 g; sc-45x; Abcam) was added to the 
reactions. Protein-DNA complexes were resolved by electrophoresis at 4ºC on 5% 
polyacrylamide gels in 0.5X TBE. Gels were dried and were subjected to 
autoradiography using a Storage Phosphor Screen (GE Healthcare). Shifted bands were 
detected using a Typhoon 9400 scanner (GE Healthcare).  
 
Induction of MMP-10 by thrombin in mouse aorta: in vivo assay  
C57Bl/6 mice (6 months old male, 30–35 g, n = 18) were procured from the colony at 
CIMA animal facilities, originating from breeders purchased from Charles River, and 
fed a normal chow diet. The research was performed in accordance with the European 
Community guidelines for ethical animal care and use of laboratory animals (Directive 
86/609), and was approved by the University of Navarra Animal Research Review 
Committee. In order to assess the role of thrombin on MMP-10 in vivo, mice were 
anesthetized by intraperitoneal injection of ketamine (50 mg/kg) and xylazine (10 
mg/kg), and thrombin (0.1-10 U, Enzyme Research Laboratory) was infused 
intravenously (tail injection). PAR-1-deficient mice in C57Bl/6 background were 
treated in a similar fashion either with saline (n=4) or 10 U thrombin (n=4).  Another set 
of C57Bl/6 mice (n=3) received TRAP-1 (6 mg/kg body weight) intravenously. 
Animals were sacrificed by CO2 inhalation 6 h after treatment and aortic arteries were 
obtained. MMP-10 mRNA levels in aorta were quantified by real-time PCR. 
Immunohistochemical analysis for MMP-10 was also performed (polyclonal antibody 
P-16, Santa Cruz Biotechnology) in aorta from mice treated with 5 U thrombin (n = 3) 
or saline (n = 3) and sacrificed 24 h after i.v. injection7. Tissue sections were 
deparaffinized, treated with 10% H2O2, immersed in 10 mM boiling citrate buffer for 10 
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min, and incubated in 10% normal horse serum for 30 min at room temperature. 
Samples were incubated with a polyclonal antibody against MMP-10 (P-16; Santa Cruz 
Biotechnology), further incubated with biotinylated anti-goat antibodies (GE 
Healthcare), and then followed by the ABC kit (Dako) with diaminobenzidine (Dako).  
 
Circulating levels of vWF and MMP-10 in patients  
Blood samples from patients with sepsis-induced disseminated intravascular 
coagulation (DIC, n = 12) were collected into 0.13 mol/L sodium citrate (9/1, v/v) kept 
on ice for no longer than 2 h and the platelet-poor plasma, obtained by centrifugation at 
2000×g for 20 min at 4°C, was stored at −70°C until used. Serum fraction of blood was 
also obtained after blood clotting (1 h), and further centrifuged (1,800 x g for 10 min) at 
room temperature. The diagnosis of overt DIC was made according to the criteria 
established by Scientific Subcommittee of DIC of the International Society on 
Thrombosis and Hemostasis (ISTH) if the score was ≥78. Specific clinical conditions 
(bleeding symptoms, organ dysfunction), and results of coagulation profile (platelet 
count, prothrombin time, fibrinogen, fibrin degradation products/D-dimer) and were 
assessed in plasma samples. Levels of von Willebrand factor (vWF) were determined in 
citrated plasma samples by ELISA following the manufacturers' instructions (vWF; 
Asserachrom, Diagnostica Stago, Gennevilliers, France), whereas MMP-10 levels were 
measured in serum samples by ELISA (R&D Systems). A group of 50 healthy subjects 
(mean age 58.2 ± 8.6 years) with no clinical history of thrombosis and normal 
coagulation screening profile, matched for age and sex (4 or 5 matches by case), were 
used as controls. In addition, we studied 60 consecutive patients (90 % men, mean age 
56 years) with previous acute myocardial infarction (previous AMI) and no history of 
malignant or autoimmune disease, coagulation disorders or presence of chronic renal 
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insufficiency (creatinine level  124 mol/L), who were under observation at the 
Cardiology Department of the University Hospital (Pamplona, Spain). Samples were 
taken between 3 and 11 months after the initial diagnosis (mean 6 months). All patients 
were treated with aspirin indefinitely and none of them was receiving oral anticoagulant 
treatment. A high proportion were also taking statins and antihypertensive therapy 
(>80%) and had increased thrombin generation9. As controls, a similarly aged group 
(n=100, 86% men, mean age 59 years) with no history of coronary artery disease 
(CAD), normal physical examination and resting electrocardiogram was enrolled. 
Informed consent was obtained from all patients according to the Declaration of 
Helsinki. 
 
MMP-10 activity assay  
Human recombinant MMP-10 (R&D systems) was incubated for 1 h at 37 ºC with or 
without 20 nM plasmin (Enzyme Research) and MMP-10 activity was measured in 96-
well microplates by using the fluorogenic peptide (MCA-Arg-Pro-Lys-Pro-Val-Glu-
Nval-Trp-Arg-Lys-[DNP]-NH2, R&D systems). Fluorescence (320 nm excitation and 
405 nm emission) was kinetically recorded on a spectrophotofluorometer (SpectraMAX 
GeminiXS, Molecular Devices). Plasmin alone was included as control. 
 
Statistical analysis 
Continuous variables were expressed as mean ± SD (unless otherwise stated). 
Differences between controls and stimulated endothelial cultures were assessed by 
Mann-Whitney-U test. Data from mice were analyzed by one-factor ANOVA to 
compare differences among groups. Differences in the baseline characteristics between 
DIC and control groups were evaluated by the Student’s t-test. Analysis of co-variance 
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(ANCOVA) was used to examine the association of MMP-10 and thrombin related 
disorders, with age and sex as covariables. Relationships between inflammatory marker 
levels, thrombin generation and MMP-10 in AMI patients were examined by Pearson 
correlation analysis, applying Bonferroni’s correction for multiple comparisons. 
Differences in functional studies between samples with recombinant MMP-10 (rMMP-
10) and controls were analyzed by the Mann-Whitney-U test. Statistical significance 
was established as p <0.05 (SPSS version 11.0). 
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